Nisa Investment Advisors LLC Cuts Position in Haemonetics Co. (NYSE:HAE)

Nisa Investment Advisors LLC trimmed its stake in Haemonetics Co. (NYSE:HAE) by 65.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 427 shares of the medical instruments supplier’s stock after selling 800 shares during the period. Nisa Investment Advisors LLC’s holdings in Haemonetics were worth $37,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HAE. AdvisorNet Financial Inc lifted its position in Haemonetics by 3,963.6% during the third quarter. AdvisorNet Financial Inc now owns 447 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 436 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in shares of Haemonetics during the 3rd quarter valued at $597,000. Boston Trust Walden Corp lifted its holdings in shares of Haemonetics by 7.7% during the 3rd quarter. Boston Trust Walden Corp now owns 720,529 shares of the medical instruments supplier’s stock valued at $64,545,000 after purchasing an additional 51,669 shares during the last quarter. First Personal Financial Services grew its stake in Haemonetics by 5.1% during the 3rd quarter. First Personal Financial Services now owns 10,498 shares of the medical instruments supplier’s stock worth $940,000 after buying an additional 510 shares during the last quarter. Finally, Raymond James & Associates increased its position in Haemonetics by 11.6% during the 3rd quarter. Raymond James & Associates now owns 32,801 shares of the medical instruments supplier’s stock valued at $2,938,000 after buying an additional 3,421 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on HAE shares. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Haemonetics in a report on Friday, April 12th.

Haemonetics Stock Up 2.9 %

Shares of HAE stock opened at $83.61 on Tuesday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $95.26. The firm has a market capitalization of $4.25 billion, a PE ratio of 33.99, a P/E/G ratio of 1.92 and a beta of 0.36. The stock’s 50-day simple moving average is $79.15 and its 200-day simple moving average is $82.65.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. The company had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. Haemonetics’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the firm posted $0.85 EPS. Equities analysts expect that Haemonetics Co. will post 3.95 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.